Free Trial

Pharming Group (NASDAQ:PHAR) Stock Price Down 4.9% - Should You Sell?

Pharming Group logo with Medical background

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) traded down 4.9% during mid-day trading on Tuesday . The stock traded as low as $10.46 and last traded at $10.47. 33,193 shares traded hands during trading, an increase of 439% from the average session volume of 6,157 shares. The stock had previously closed at $11.00.

Analysts Set New Price Targets

PHAR has been the subject of a number of research reports. Oppenheimer raised their price target on shares of Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a report on Friday, March 14th. HC Wainwright restated a "buy" rating and issued a $37.00 target price on shares of Pharming Group in a research note on Thursday, March 20th.

Read Our Latest Research Report on Pharming Group

Pharming Group Stock Down 2.5%

The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.00 and a current ratio of 2.76. The stock's 50 day simple moving average is $10.38 and its 200 day simple moving average is $9.41. The firm has a market cap of $706.16 million, a P/E ratio of -51.90 and a beta of 0.02.

Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.03. Pharming Group had a negative net margin of 4.14% and a negative return on equity of 6.01%. The business had revenue of $79.09 million for the quarter, compared to analysts' expectations of $67.74 million. Research analysts anticipate that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current year.

About Pharming Group

(Get Free Report)

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Recommended Stories

Should You Invest $1,000 in Pharming Group Right Now?

Before you consider Pharming Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.

While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The $2.5B Merger No One Is Talking About
ALERT: Big Tech Earnings – Watch Before Wednesday
ACT FAST! Congress is Dumping these 3 Stocks

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines